Susanne Hodgson

Dr Susanne Hodgson is a Clinician Scientist and NDM Career Development Fellow at the University of Oxford, serving as an Honorary Consultant Physician in Infectious Diseases and Microbiology while holding a Clinical Lecturer position at St Peter's College. She leads the Gonococcal Vaccine Project at the Jenner Institute with extensive experience in early-phase vaccine development and efficacy testing across UK and low-income settings.

Her research centers on controlled human infection models to evaluate vaccine efficacy against complex pathogens, with special focus on gonorrhea, malaria, and surgical infections. She pioneers translational approaches bridging laboratory immunology with field applications in resource-limited regions, addressing antimicrobial resistance through novel vaccine strategies and optimizing trial communication to build public confidence.

Analysis of her 2023-2025 publications reveals critical contributions across infectious disease domains: gonorrhea antimicrobial resistance patterns, ethical frameworks for vaccine trial communication, malaria vaccine immunogenicity in vulnerable populations, and evidence-based management of necrotizing infections. These works demonstrate her interdisciplinary methodology integrating clinical medicine, immunology, and public health to solve urgent global health challenges.

No scientific awards are documented in the provided materials, though her leadership in high-impact vaccine initiatives indicates significant professional recognition. As principal investigator for the Gonococcal Vaccine Project, she manages substantial research funding while mentoring junior scientists in clinical trial methodology and global health research ethics.

Dr Hodgson directs the Gonococcal Vaccine Project team within the Nuffield Department of Medicine, which operates at the intersection of laboratory science and clinical field studies. The team maintains active collaborations with African research institutions to ensure vaccine development addresses real-world epidemiological needs, particularly in malaria-endemic and antimicrobial resistance hotspots.